<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04678557</url>
  </required_header>
  <id_info>
    <org_study_id>VC01-103</org_study_id>
    <nct_id>NCT04678557</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus</brief_title>
  <acronym>VC01-103</acronym>
  <official_title>An Open-Label Phase 1/2 Study to Evaluate the Safety, Engraftment, and Efficacy of VC-01™Combination Product in Subjects With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViaCyte</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ViaCyte</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      VC01-103 will evaluate an experimental combination product, cell replacement therapy intended&#xD;
      to provide a functional cure to subjects with Type 1 Diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial will test if VC-01 combination product can be implanted and maintained with&#xD;
      safety, tolerability, and efficacy for up to Month 12/Week 52.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2019</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>There are two Cohorts in this study design. Cohort 1 (Phase 1) enrolls up to 30 subjects total. After Cohort 1 enrollment is completed, Cohort 2 enrollment then occurs with up to an additional 40 subjects. A total of up to 70 subjects will be enrolled under this Phase 1/2 protocol.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cohort 1: The percentage of graft cells present at post-implant time points relative to pre-clinical models</measure>
    <time_frame>Up to 26 weeks</time_frame>
    <description>Assess via histology the potential for functional engraftment of VC-01 combination product</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 2: The change in AUC from baseline to Week 26 in C-peptide during 4-HR MMTT</measure>
    <time_frame>To Week 26</time_frame>
    <description>Evaluate the clinical efficacy of VC-01 combination product.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Sentinel units (aka Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VC-01 Combination Product; Up to ten (10) VC-01 sentinels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-finding units (aka Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VC-01 Combination Product; Up to twelve units implanted of which up to nine (9) are VC-01-DF (dose-finding) implants and the rest are VC-01 sentinels</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>VC-01 Combination Product</intervention_name>
    <description>PEC-01 cells loaded into an Encaptra Drug Delivery System</description>
    <arm_group_label>Dose-finding units (aka Cohort 2)</arm_group_label>
    <arm_group_label>Sentinel units (aka Cohort 1)</arm_group_label>
    <other_name>PEC-Encap</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and non-pregnant women&#xD;
&#xD;
          -  Diagnosis of T1DM for a minimum of 3 years.&#xD;
&#xD;
          -  Stable, optimized diabetic regimen&#xD;
&#xD;
          -  Acceptable candidate for implant and explant procedures.&#xD;
&#xD;
          -  Willing and able to comply with protocol requirements.&#xD;
&#xD;
          -  Meet insulin dosing requirements per protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        • Advanced complications associated with diabetes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Foyt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ViaCyte, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Operations</last_name>
    <phone>858-207-0500</phone>
    <email>info@viacyte.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AMCR Institute</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Galdes</last_name>
      <phone>925-930-7267</phone>
      <phone_ext>226</phone_ext>
      <email>egaldes@diabloclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>404-355-4393</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Diabetes &amp; Endocrinology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>512-458-8400</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.viacyte.com</url>
    <description>PEC-Encap VC-01</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2020</study_first_posted>
  <last_update_submitted>February 26, 2021</last_update_submitted>
  <last_update_submitted_qc>February 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

